# **Faculty**



Dr. Mrugesh Vaishnav (IPS President)



Dr. Vinay Kumar (IPS General Secretary) (Chairperson)



Dr. Nilesh Shah (Chairperson)



Dr. Aleem Siddiqui (Chairperson)




Dr. Ashit Sheth (Panelist)



Dr. Rajeev Gupta (Panelist)



Prof. Nand Kumar (Panelist)





# Invitation

#### Dear Colleagues,

TRD poses a dire challenge to the field of clinical psychiatry and is experienced by 45% of patients with a major depressive disorder. Highly associated with suicidal ideation and suicide attempts, TRD contributes to nearly one-third of patients attempting suicide in their lifetime. Despite advances in the understanding of the psychopharmacology and biomarkers of major depression and the introduction of several novel classes of antidepressants, only 60%–70% of patients with depression respond to antidepressant therapy. Once a mainstay of antidepressant treatment, MAOIs have largely been abandoned in favor of medications with suggested improved safety profiles. However, while newer agents undoubtedly have more attractive risk profiles, MAOIs should not be ruled out as a therapeutic option and should continue to play a role in the management of patients with atypical depression, bipolar depression and most importantly treatment-resistant depression. Patients with treatment-resistant depression require long-term antidepressant treatment, and MAOIs do appear to have long-term efficacy.

CME Foundation of India is pleased to announce an exclusive summit on MAOIs – Focus on Tranylcypromine to be held at JW Marriott, Mumbai on 25<sup>th</sup> August 2019. This summit aims to educate about MAOIs, their place in depression treatment which will immensely benefit the participants in their day to day practice. The faculty includes national and international experts who have extensive in-clinic experience with MAOIs.

Looking forward to see you in Mumbai.

### **Course Director**

### Prof. Chittaranjan Andrade



Dr. Andrade is Dean and Head of the department of psychopharmacology (NIMHANS) with over three decades of experience in psychiatry.

He has received 3 international awards, 11 national awards (including all the major awards of the Indian Psychiatric Society) and 8 state and other awards in recognition of his research. He has published more than 20 books, about 40 chapters in various textbooks, and around 500 scientific papers in peer-reviewed journals. His work has received over 3500 citations in the scientific literature.

#### Scientific Agenda

Time	Topic	Speaker
9.00-9.45 am	Registration	37.11.100
9.45-10.00 am	Inauguration by Dr. Mrugesh Vaishnav	
10.00-10.45 am	MAOIs: Introduction and Need-to-know Pharmacology for the Practising Psychiatrist	Dr. Chittaranjan Andrade
10.45-11.00 am	Tea Break	
11.00 am-12 noon	Tranylcypromine: Phoenix	Dr. Ken Gillman
12.00-1.00 pm	Using Tranylcypromine in Difficult-to-Treat Depression: A Practical Guide	Dr. Rajnish Mago
1.00-1.15 pm	Summing up the summit	Dr. Ashit Sheth
1.15-2.30 pm	Lunch Break	

## **International Speakers**

#### Dr. P. Ken Gillman (Australia)



MRCPsych, a retired academic & clinical psychiatrist hailed by Stephen Stahl as "the world's foremost authority on MAOIs and diet and drug interactions," has published a comprehensive review on the dietary tyramine and drug interactions relevant to MAOIs, while also addressing common myths that has hindered the use of these agents.

#### Dr. Rajnish Mago (USA)



Dr. Rajnish Mago is a psychiatrist in Philadelphia, Pennsylvania. He received his medical degree from King George's/CSM Medical College and has been in practice for more than 20 years. His specialties include Psychosomatic Medicine, Psychiatry and Neurology. He is the Editor-in-Chief of an acclaimed website for educating mental health clinicians: simpleandpractical.com. He is a psychiatrist on the faculty in the Department of Psychiatry at the University of Pennsylvania where he is the director of the psychopharmacology curriculum.

